Sanofi Drug AYVAKIT® Shows Long-Term Efficacy
Sanofi subsidiary Blueprint Medicines has released four-year data showing its drug AYVAKIT® provides sustained benefits and long-term safety for patients with the rare disorder indolent systemic mastocytosis. The findings, presented at the 2026 AAAAI Annual Meeting, reinforce the drug's standing as a leading therapy for the condition.
Indolent systemic mastocytosis (ISM) is a rare, chronic blood disorder characterized by the abnormal accumulation of mast cells in various tissues. This buildup can cause a wide range of debilitating symptoms, including skin lesions, gastrointestinal issues, severe allergic reactions, and cognitive difficulties. AYVAKIT's active ingredient, avapritinib, is a precision therapy that targets the primary underlying driver of the disease. In approximately 95% of cases, systemic mastocytosis is caused by a specific genetic mutation known as KIT D816V, which this drug is designed to potently and selectively inhibit. The U.S. Food and Drug Administration (FDA) initially approved AYVAKIT for advanced systemic mastocytosis in June 2021. Its approval was expanded to include indolent systemic mastocytosis in May 2023, making it the first and only medicine approved to treat this more common form of the disease. The long-term data from the PIONEER clinical trial highlighted not only sustained symptom improvement but also a favorable safety profile, with a low discontinuation rate of 3% due to treatment-related adverse events over a median follow-up of nearly four years. The study also showed the drug increased bone mineral density, suggesting it may have disease-modifying effects. The drug's developer, Blueprint Medicines, was acquired by Sanofi in a deal announced in June 2025 and finalized the following month. The acquisition, valued at approximately $9.1 billion, was a strategic move by Sanofi to bolster its portfolio in rare immunological diseases. Through the acquisition, Sanofi also gained control of Blueprint's pipeline, including elenestinib, a next-generation KIT inhibitor being studied for systemic mastocytosis. This positions Sanofi for continued leadership in treating this rare condition throughout the next decade.
